

Invitation to presentation of Xbrane Biopharma's Year-end report 2022 on February 17, 2023.

Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE), invites to a teleconference for investors, analysts and media on Friday, February 17, 2023, at 10.00 a.m. CET. Xbrane will publish the company's Year-end report 2022, on Friday, February 17, 2023, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the Year-end report 2022, followed by a Q&A session. The presentation will be in English. To attend, please follow the link or dial-in at one of the numbers below:

Web link:

Webcast URL

<https://edge.media-server.com/mmc/p/syxw4qq6>

Conference call dial in details, Participants:

Online Registration:

<https://register.vevent.com/register/BI875d79843368447494c388901b23019e>

Contacts

Martin Åmark, CEO

M: +46 76 309 37 77

E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR

M: +46 76 325 60 90

E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and is launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Press Release
14 February 2023 10:00:00 CET



Attachments

[Invitation to presentation of Xbrane Biopharma's Year-end report 2022 on February 17, 2023.](#)